OPKO Health (NASDAQ:OPK) Releases Earnings Results, Meets Estimates

OPKO Health (NASDAQ:OPK) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07), FiscalAI reports. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The firm had revenue of $130.83 million during the quarter, compared to analyst estimates of $136.62 million. During the same quarter in the previous year, the business posted $0.03 EPS. OPKO Health’s revenue was down 56.9% on a year-over-year basis.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO agreed to sell substantially all of BioReference’s remaining operations to Labcorp for about $722 million in cash, with potential 4Kscore royalties of up to $150 million over 10 years. The deal, which remains subject to customary closing conditions, would complete OPKO’s exit from diagnostics and refocus it on biotech and global products.
• Continuing-operations revenue rose 16% to $65.4 million year over year, led by OPKO Iberoamerica, RAYALDEE and mazdutide royalties. Global products reported $6 million of operating income, versus a $1.2 million loss a year earlier.
• Pipeline programs advanced, including completion of enrollment in the planned phase I cohorts for MDX-2301, with management describing its blinded safety profile as favorable. OPKO is preparing subcutaneous dosing studies for several ModeX candidates, while its first in vivo CAR-T program is now targeted for first-in-human studies in mid-2027, later than previously planned.
• Innovative biotech’s operating loss widened to $26.8 million from $22.5 million, as increased research and development activity raised costs. OPKO expects about $125 million in BioReference sale-related costs, and forecast a roughly $40 million loss from discontinued operations in Q4.
• OPKO ended the quarter with $403.2 million in cash, cash equivalents and restricted cash, and repurchased 7.2 million shares for $10.6 million. It withdrew consolidated full-year guidance and issued continuing-operations revenue guidance of $268 million–$278 million; management said it would provide more detail on capital allocation as the Labcorp closing approaches.

OPKO Health Stock Performance

NASDAQ:OPK traded up $0.05 during mid-day trading on Wednesday, hitting $1.77. The company’s stock had a trading volume of 4,819,446 shares, compared to its average volume of 5,615,405. The business’s fifty day moving average is $1.58 and its two-hundred day moving average is $1.35. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -19.67 and a beta of 1.52. OPKO Health has a 1 year low of $0.98 and a 1 year high of $1.81. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Barrington Research upgraded shares of OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 target price for the company in a research note on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th. Piper Sandler reissued an “overweight” rating and issued a $4.00 price objective (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Zacks Research upgraded OPKO Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Finally, UBS Group set a $4.00 target price on OPKO Health in a research report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $3.42.

More OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO agreed to sell substantially all of its remaining BioReference diagnostic operations to Labcorp for $722 million in cash. The proceeds could strengthen OPKO’s financial position, although the sale also means exiting those diagnostic operations. OPKO Health Q3 2026 results and business highlights
• Neutral Sentiment: OPKO reported a quarterly loss of $0.07 per share, in line with the consensus estimate. OPKO Health earnings report
• Negative Sentiment: Revenue missed the $136.6 million FactSet estimate. Coverage differs on the reported amount—one flash report cited $65.4 million, while another reported $130.8 million—so investors may seek clarification. The latter report also said revenue fell 56.9% year over year, raising concern about the operating trend. Earnings flash on OPKO revenue OPKO Q3 earnings estimate coverage

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.